A5077301130- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- Cancer Mechanisms and Therapy
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
- Liver Disease Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Medical Imaging Techniques and Applications
- Cancer Treatment and Pharmacology
- Advanced Radiotherapy Techniques
- PI3K/AKT/mTOR signaling in cancer
Pirogov Russian National Research Medical University
2019-2025
Ministry of Health
2019-2025
Ministry of Health of the Russian Federation
2017-2025
Sarah Cannon
2024
Peking University Cancer Hospital
2024
Tennessee Oncology
2024
Zhengzhou University
2024
Peking University
2024
Henan Cancer Hospital
2024
Université Paris-Saclay
2023
Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant are unknown.
PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D CT) (D versus alone (CT) in first-line metastatic non–small-cell lung cancer (mNSCLC). METHODS Patients (n = 1,013) with EGFR/ ALK wild-type mNSCLC were randomly assigned (1:1:1) to 75 mg 1,500 platinum-based for up four 21-day cycles, followed by once every 4 weeks until progression one additional dose; progression; or six cycles (with without maintenance pemetrexed; all arms)....
Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that selective for EGFR-TKI-sensitizing and
The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30];
Abstract First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free (PFS) versus chemotherapy patients with advanced non-small lung cancer (aNSCLC) PD-ligand 1 (PD-L1) expression ≥50%. EMPOWER-Lung 3 ( NCT03409614 ), a double-blind, placebo-controlled, phase study, examined plus platinum-doublet as first-line treatment for aNSCLC, irrespective of PD-L1 or histology. In this 466 stage...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co‐primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We report 5-year phase III KEYNOTE-042 study (ClinicalTrials.gov identifier: NCT02220894 ). Eligible patients with...
BackgroundCheckMate 171 (NCT02409368) is an open-label, multicentre, phase 2 trial of nivolumab in previously treated advanced squamous non-small cell lung cancer (NSCLC), conducted as part a post-approval commitment to the European Medicines Agency (EMA). We report outcomes from this trial.MethodsPatients with Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2 and disease progression during/after ≥1 systemic treatment (≥1 being platinum-based chemotherapy) for or metastatic...
Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found have a clinically meaningful improvement disease-free survival (DFS) IB EGFR-mutated (EGFRm) NSCLC. Here, we report prespecified and exploratory analyses of adjuvant use outcomes from ADAURA.Patients EGFRm NSCLC were randomized 1:1 receive or placebo for years. before randomization not...
We report CNS efficacy of first-line osimertinib plus chemotherapy versus monotherapy in patients with epidermal growth factor receptor (
Adjuvant therapy with durvalumab, or without tremelimumab, may have efficacy in patients limited-stage small-cell lung cancer who do not disease progression after standard concurrent platinum-based chemoradiotherapy.
EMPOWER-Lung 3 part 2 (NCT03409614), a double-blind, placebo-controlled phase study, investigated cemiplimab (antiprogrammed cell death protein 1) plus chemotherapy versus placebo in patients with advanced NSCLC without EGFR, ALK, or ROS1 aberrations, either squamous nonsquamous histology, irrespective of programmed death-ligand 1 levels. At primary analysis, after 16.4 months follow-up, improved median overall survival (OS) alone (21.9 13.0 mo, hazard ratio [HR] = 0.71, 95% confidence...
LBA5 Background: The standard of care (SoC) for pts with LS-SCLC is concurrent platinum-based chemoradiotherapy (cCRT) ± prophylactic cranial irradiation (PCI). ADRIATIC (NCT03703297), a phase 3, randomized, double-blind, placebo (PBO)-controlled, multicenter, global study, assessed D tremelimumab (T) as consolidation tx who had not progressed after cCRT. Here we report results vs PBO from the first planned interim analysis (IA). Methods: Eligible stage I–III (stage I/II inoperable) and WHO...
Lung cancer is the major human malignancy, accounting for 30% of all cancer-related deaths worldwide. Poor survival lung patients, together with late diagnosis and resistance to classic chemotherapy, highlights need identification new biomarkers early detection. Among different biomarkers, small non-coding RNAs called microRNAs (miRNAs) are considered most promising, owing their remarkable stability, cancer-type specificity, presence in body fluids. However, results multiple previous...
In the phase 3 KEYNOTE-407 study, addition of pembrolizumab to carboplatin-paclitaxel/nab-paclitaxel significantly improved overall survival, progression-free and objective response rate in patients with previously untreated metastatic squamous non-small-cell lung cancer (NSCLC), little impact on severe toxicity. We present patient-reported outcomes (PROs) from KEYNOTE-407.Patients were randomly assigned receive 4 cycles 200 mg or placebo once every weeks plus carboplatin paclitaxel...
8005 Background: Osimertinib (osi) is a third-generation, central nervous system-active EGFR-TKI, that potently and selectively inhibits EGFR-TKI sensitizing EGFR T790M resistance mutations. Adj osi (3 years [yrs]) recommended for resected EGFRm stage IB–IIIA NSCLC, based on significant improvements in disease-free survival (DFS) overall (OS) the Phase III ADAURA study (NCT02511106). A trend towards an increased DFS event rate beyond 3 yrs suggests some pts may benefit from longer adj...
Osimertinib—a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor—is recommended as adjuvant therapy for resected stage IB–IIIA receptor-mutated non-small-cell lung cancer, based on significant disease-free survival (DFS) and overall improvement shown in the previously reported phase 3 ADAURA trial. A trend toward an increased DFS event rate after completion of years treatment suggests that some patients may benefit from longer osimertinib treatment. We therefore...
The primary analysis (median follow-up 34.9 mo across all arms) of the phase 3 POSEIDON study revealed a statistically significant overall survival (OS) improvement with first-line tremelimumab plus durvalumab and chemotherapy (T+D+CT) versus CT in patients EGFR ALK wild-type metastatic NSCLC (mNSCLC). D+CT had trend for OS that did not reach statistical significance. This article reports prespecified analyses after long-term >5 y). A total 1013 were randomized (1:1:1) to T+D+CT, D+CT, or...
Background: Pembro significantly improved OS vs chemo as first-line therapy in pts with PD-L1–positive locally advanced/metastatic NSCLC without EGFR/ALK alterations after median follow-up of 12.8 mo based on interim analysis KEYNOTE-042 (NCT02220894). We present the final protocol-specified an additional 6 follow-up. Methods: Pts were randomized 1:1 to 35 cycles pembro 200 mg Q3W or (6 paclitaxel/pemetrexed [pem] + carboplatin optional pem maintenance [nonsquamous only]), stratified by...
Abstract Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit completely resected stage IB–IIIA EGFR-mutated (EGFRm) non–small cell lung cancer (NSCLC). We report health-related quality of life (HRQoL) outcomes from ADAURA. Patients Methods: randomized 1:1 received oral 80 mg or placebo for 3 years until...
General data. The article presents the results of a comparative analysis effectiveness integrated chemotherapy in targeted anti-EGFR therapy for patients with non-small cell lung cancer (NSCLC) mutation exon 21 EGFR gene compared to monotherapy firstand second-generation tyrosine kinase inhibitors (TKIs). Material: From 2015 2021, study included 45 metastatic NSCLC L858R first line treatment, distributed into an experimental group and control 23 22 people, respectively. Patients received 2...